Interpace Biosciences, Inc. announced that Thomas Freeburg, the Chief Financial Officer resigned from his position as Chief Financial Officer and as an employee of the Company. Pursuant to a Severance and Consulting Agreement and General Release between the Company and Mr. Freeburg (the “Consulting Agreement”) effective September 30, 2022, Mr. Freeburg will provide certain consulting services to the Company, including finance and accounting services, as requested or deemed appropriate by the Company's Chief Executive Officer and/or other senior management employees. Mr. Freeburg will continue to act as the Company's principal financial officer during the Consulting Term, until such time as the Company recruits a new Chief Financial Officer to replace Mr. Freeburg.